Sarepta Therapeutics Inc. (NASDAQ:SRPT)‘s stock had its “outperform” rating reissued by investment analysts at RBC Capital Markets in a report issued on Monday. They presently have a $108.00 target price on the stock. RBC Capital Markets’ target price points to a potential upside of 106.58% from the company’s previous close.
SRPT has been the subject of a number of other reports. Oppenheimer Holdings Inc. restated a “buy” rating and issued a $60.00 target price on shares of Sarepta Therapeutics in a research note on Sunday, July 17th. Jefferies Group set a $58.00 target price on Sarepta Therapeutics and gave the company a “hold” rating in a research note on Sunday, October 2nd. Robert W. Baird restated an “outperform” rating and issued a $102.00 target price on shares of Sarepta Therapeutics in a research note on Monday. William Blair upgraded Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $88.00 target price for the company in a research note on Monday, September 19th. Finally, Piper Jaffray Cos. upgraded Sarepta Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Monday, September 19th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. Sarepta Therapeutics presently has an average rating of “Buy” and an average price target of $60.91.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded down 4.38% during midday trading on Monday, hitting $49.99. 2,807,084 shares of the company were exchanged. The company’s 50 day moving average price is $45.03 and its 200 day moving average price is $26.60. The firm’s market cap is $2.39 billion. Sarepta Therapeutics has a one year low of $8.00 and a one year high of $63.73.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by $0.16. During the same period in the prior year, the business posted ($0.87) earnings per share. Equities analysts expect that Sarepta Therapeutics will post ($4.23) EPS for the current year.
In other Sarepta Therapeutics news, SVP David T. Howton sold 7,000 shares of the stock in a transaction dated Thursday, September 22nd. The stock was sold at an average price of $60.00, for a total value of $420,000.00. Following the transaction, the senior vice president now owns 28,453 shares of the company’s stock, valued at $1,707,180. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Edward M. Md Kaye sold 24,557 shares of the stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total value of $736,710.00. Following the completion of the transaction, the chief executive officer now directly owns 76,983 shares in the company, valued at approximately $2,309,490. The disclosure for this sale can be found here. 10.90% of the stock is owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in SRPT. Vanguard Group Inc. raised its position in Sarepta Therapeutics by 5.5% in the second quarter. Vanguard Group Inc. now owns 3,105,816 shares of the company’s stock valued at $59,227,000 after buying an additional 161,790 shares during the last quarter. State Street Corp raised its stake in Sarepta Therapeutics by 25.3% in the second quarter. State Street Corp now owns 3,092,427 shares of the company’s stock worth $58,976,000 after buying an additional 625,051 shares in the last quarter. BlackRock Fund Advisors raised its stake in Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock worth $32,439,000 after buying an additional 36,371 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in Sarepta Therapeutics by 2.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,068,913 shares of the company’s stock worth $20,865,000 after buying an additional 25,799 shares in the last quarter. Finally, Franklin Resources Inc. acquired a new stake in Sarepta Therapeutics during the first quarter worth approximately $13,506,000. 65.06% of the stock is currently owned by hedge funds and other institutional investors.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.